Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lisa I. Glasser"'
Autor:
Brandon J. Patterson, Chi-Chang Chen, Catherine B. McGuiness, Lisa I. Glasser, Kainan Sun, Philip O. Buck
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 8, Pp 2482-2487 (2021)
Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 in the United States (US) for the prevention of herpes zoster in adults aged 50 years and older. The vaccine is administered in two doses, with the second dose administration rec
Externí odkaz:
https://doaj.org/article/bd2f14ee610347a897c679c0756248fc
Autor:
Serge A. Jabbour, Lisa I. Glasser, Brandon J. Patterson, Saurabh P. Nagar, Juliana L. Meyers, Jean-Etienne Poirrier
Objective Data on real-world burden of herpes zoster (HZ) in adults with type 2 diabetes mellitus (T2D) in the U.S. are limited. We assessed HZ in patients with and without T2D and measured the impact of HZ on healthcare resource use (HCRU) and costs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c469ef0d5bd37c5c66d1a1d15288f05
https://doi.org/10.2337/figshare.20736703
https://doi.org/10.2337/figshare.20736703
Autor:
Philip O. Buck, Lisa I Glasser, Catherine Balderston McGuiness, Kainan Sun, Brandon J. Patterson, Chi-Chang Chen
Publikováno v:
Human Vaccines & Immunotherapeutics
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 in the United States (US) for the prevention of herpes zoster in adults aged 50 years and older. The vaccine is administered in two doses, with the second dose administration rec
Autor:
Kainan Sun, Lisa I Glasser, Siyu Ma, Brandon J. Patterson, Catherine Balderston McGuiness, Chi-Chang Chen, Philip O. Buck
Publikováno v:
Journal of the American Pharmacists Association. 62:526-536.e10
Background/Objectives Vaccination against herpes zoster (HZ) is an effective strategy in protecting the population against consequences of varicella zoster virus reactivation. Optimal immunogenicity with recombinant zoster vaccine (RZV) relies on com
Autor:
Lisa I Glasser, Brandon J. Patterson, Chi-Chang Chen, Kainan Sun, Philip O. Buck, Catherine Balderston McGuiness
Publikováno v:
Open Forum Infectious Diseases
Background Recombinant Zoster Vaccine (RZV) was licensed in the United States (US) in October 2017 for the prevention of herpes zoster in adults ≥ 50 years of age (YOA). The vaccine is administered in a two-dose sequence with a 2- to 6-month interv